JP2019511564A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019511564A5 JP2019511564A5 JP2018560435A JP2018560435A JP2019511564A5 JP 2019511564 A5 JP2019511564 A5 JP 2019511564A5 JP 2018560435 A JP2018560435 A JP 2018560435A JP 2018560435 A JP2018560435 A JP 2018560435A JP 2019511564 A5 JP2019511564 A5 JP 2019511564A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- alkyl
- atom bonded
- compound
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 36
- 150000001875 compounds Chemical class 0.000 claims 24
- 229910052799 carbon Inorganic materials 0.000 claims 15
- 125000005843 halogen group Chemical group 0.000 claims 15
- 229910052757 nitrogen Inorganic materials 0.000 claims 15
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 15
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 14
- -1 nitro, cyano, amino Chemical group 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 102000001253 Protein Kinase Human genes 0.000 claims 8
- 108060006633 protein kinase Proteins 0.000 claims 8
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 claims 6
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 125000004432 carbon atom Chemical group C* 0.000 claims 6
- 102000003989 Aurora kinases Human genes 0.000 claims 5
- 108090000433 Aurora kinases Proteins 0.000 claims 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 4
- 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 claims 4
- 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 201000001441 melanoma Diseases 0.000 claims 4
- 102100036725 Epithelial discoidin domain-containing receptor 1 Human genes 0.000 claims 3
- 101710131668 Epithelial discoidin domain-containing receptor 1 Proteins 0.000 claims 3
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims 3
- 102000002576 MAP Kinase Kinase 1 Human genes 0.000 claims 3
- 108010068342 MAP Kinase Kinase 1 Proteins 0.000 claims 3
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 3
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims 3
- 102000001332 SRC Human genes 0.000 claims 3
- 108060006706 SRC Proteins 0.000 claims 3
- 206010039491 Sarcoma Diseases 0.000 claims 3
- 102100027053 Tyrosine-protein kinase Blk Human genes 0.000 claims 3
- 101710083476 Tyrosine-protein kinase Blk Proteins 0.000 claims 3
- 108091008605 VEGF receptors Proteins 0.000 claims 3
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims 3
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 claims 3
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 3
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 3
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 claims 3
- 108010003374 fms-Like Tyrosine Kinase 3 Proteins 0.000 claims 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010005949 Bone cancer Diseases 0.000 claims 2
- 208000018084 Bone neoplasm Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 2
- 102100035108 High affinity nerve growth factor receptor Human genes 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 101000912503 Homo sapiens Tyrosine-protein kinase Fgr Proteins 0.000 claims 2
- 206010021042 Hypopharyngeal cancer Diseases 0.000 claims 2
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 108700020796 Oncogene Proteins 0.000 claims 2
- 206010031096 Oropharyngeal cancer Diseases 0.000 claims 2
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000007452 Plasmacytoma Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 102100026150 Tyrosine-protein kinase Fgr Human genes 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 2
- 208000026900 bile duct neoplasm Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000002124 endocrine Effects 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 208000024519 eye neoplasm Diseases 0.000 claims 2
- 201000010175 gallbladder cancer Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 208000003884 gestational trophoblastic disease Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 201000006866 hypopharynx cancer Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 201000005831 male reproductive organ cancer Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000009826 neoplastic cell growth Effects 0.000 claims 2
- 230000001537 neural effect Effects 0.000 claims 2
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims 2
- 201000008106 ocular cancer Diseases 0.000 claims 2
- 201000006958 oropharynx cancer Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 102200039431 rs121913488 Human genes 0.000 claims 2
- 102200006095 rs77724903 Human genes 0.000 claims 2
- 102200006097 rs79658334 Human genes 0.000 claims 2
- 201000002314 small intestine cancer Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- 241000282324 Felis Species 0.000 claims 1
- 101000596894 Homo sapiens High affinity nerve growth factor receptor Proteins 0.000 claims 1
- 101000850794 Homo sapiens Tropomyosin alpha-3 chain Proteins 0.000 claims 1
- 102000045959 Interleukin-1 Receptor-Like 1 Human genes 0.000 claims 1
- 108700003107 Interleukin-1 Receptor-Like 1 Proteins 0.000 claims 1
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 claims 1
- 101710087603 Mast/stem cell growth factor receptor Kit Proteins 0.000 claims 1
- 108091008606 PDGF receptors Proteins 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 claims 1
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 claims 1
- 102100033080 Tropomyosin alpha-3 chain Human genes 0.000 claims 1
- 102100026857 Tyrosine-protein kinase Lyn Human genes 0.000 claims 1
- 101710088331 Tyrosine-protein kinase Lyn Proteins 0.000 claims 1
- 102100021788 Tyrosine-protein kinase Yes Human genes 0.000 claims 1
- 101710107570 Tyrosine-protein kinase Yes Proteins 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 230000009977 dual effect Effects 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 125000004001 thioalkyl group Chemical group 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 0 Cc1cc(-c2cnc(Nc3nc(C)nc(N4CCN(CCI)CC4)c3)[s]2)ccc1NC(NC1=N*C(C2CC2)=C1)=O Chemical compound Cc1cc(-c2cnc(Nc3nc(C)nc(N4CCN(CCI)CC4)c3)[s]2)ccc1NC(NC1=N*C(C2CC2)=C1)=O 0.000 description 4
- HWTSERGWWBBNRB-UHFFFAOYSA-N CCc1cc(NC(Nc(cc2)ccc2-c2cnc(Nc3nc(C)nc(N4CCN(CCO)CC4)c3)[s]2)=O)n[o]1 Chemical compound CCc1cc(NC(Nc(cc2)ccc2-c2cnc(Nc3nc(C)nc(N4CCN(CCO)CC4)c3)[s]2)=O)n[o]1 HWTSERGWWBBNRB-UHFFFAOYSA-N 0.000 description 2
- AAZWOYHDKCZELR-UHFFFAOYSA-N CC(C)(C)c1cc(NC(Nc(cc2)c(C)cc2-c2cnc(Nc3nc(C)nc(N4CCN(CCO)CC4)c3)[s]2)=O)n[o]1 Chemical compound CC(C)(C)c1cc(NC(Nc(cc2)c(C)cc2-c2cnc(Nc3nc(C)nc(N4CCN(CCO)CC4)c3)[s]2)=O)n[o]1 AAZWOYHDKCZELR-UHFFFAOYSA-N 0.000 description 1
- QILCGQUUZGDEJE-UHFFFAOYSA-N CCCN(CC1)CCN1c1cc(Nc2ncc(-c(cc3C)ccc3NC(Nc3n[o]c(CC)c3)=O)[s]2)nc(SC)n1 Chemical compound CCCN(CC1)CCN1c1cc(Nc2ncc(-c(cc3C)ccc3NC(Nc3n[o]c(CC)c3)=O)[s]2)nc(SC)n1 QILCGQUUZGDEJE-UHFFFAOYSA-N 0.000 description 1
- UZLXIMKAXYTBNH-UHFFFAOYSA-N CCc1cc(NC(Nc(c(C)c2)ccc2-c2cnc(Nc3nc(C)nc(N4CCN(CCO)CC4)c3)[s]2)=O)n[o]1 Chemical compound CCc1cc(NC(Nc(c(C)c2)ccc2-c2cnc(Nc3nc(C)nc(N4CCN(CCO)CC4)c3)[s]2)=O)n[o]1 UZLXIMKAXYTBNH-UHFFFAOYSA-N 0.000 description 1
- PAPZQLQHTIAXCM-UHFFFAOYSA-N CCc1cc(NC(Nc(c(C)c2)ccc2-c2cnc(Nc3nc(SC)nc(N4CCN(CCO)CC4)c3)[s]2)=O)n[o]1 Chemical compound CCc1cc(NC(Nc(c(C)c2)ccc2-c2cnc(Nc3nc(SC)nc(N4CCN(CCO)CC4)c3)[s]2)=O)n[o]1 PAPZQLQHTIAXCM-UHFFFAOYSA-N 0.000 description 1
- LPHIYODDPREOBQ-UHFFFAOYSA-N CCc1cc(NC(Nc(cc2)ccc2-c2cnc(Nc3nc(C)nc(N4CCN(CCF)CC4)c3)[s]2)=O)n[o]1 Chemical compound CCc1cc(NC(Nc(cc2)ccc2-c2cnc(Nc3nc(C)nc(N4CCN(CCF)CC4)c3)[s]2)=O)n[o]1 LPHIYODDPREOBQ-UHFFFAOYSA-N 0.000 description 1
- TXBJBHBDLIYNMC-UHFFFAOYSA-N Cc(cc(cc1)-c2cnc(Nc3nc(C)nc(N4CCN(CCO)CC4)c3)[s]2)c1NC(Nc1n[o]c(C2CC2)c1)=O Chemical compound Cc(cc(cc1)-c2cnc(Nc3nc(C)nc(N4CCN(CCO)CC4)c3)[s]2)c1NC(Nc1n[o]c(C2CC2)c1)=O TXBJBHBDLIYNMC-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662291667P | 2016-02-05 | 2016-02-05 | |
| US62/291,667 | 2016-02-05 | ||
| PCT/US2017/015765 WO2017136315A1 (en) | 2016-02-05 | 2017-01-31 | Aminothiazole compounds and use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019511564A JP2019511564A (ja) | 2019-04-25 |
| JP2019511564A5 true JP2019511564A5 (enExample) | 2019-11-14 |
| JP6883049B2 JP6883049B2 (ja) | 2021-06-02 |
Family
ID=59496120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018560435A Active JP6883049B2 (ja) | 2016-02-05 | 2017-01-31 | アミノチアゾール化合物及びその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10047078B2 (enExample) |
| EP (1) | EP3411035B1 (enExample) |
| JP (1) | JP6883049B2 (enExample) |
| KR (1) | KR102449712B1 (enExample) |
| CN (1) | CN109069504B (enExample) |
| ES (1) | ES2909612T3 (enExample) |
| TW (1) | TWI620748B (enExample) |
| WO (1) | WO2017136315A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011256380C1 (en) | 2010-05-20 | 2016-09-08 | Array Biopharma Inc. | Macrocyclic compounds as Trk kinase inhibitors |
| JP6816100B2 (ja) | 2015-07-16 | 2021-01-20 | アレイ バイオファーマ、インコーポレイテッド | ＲＥＴキナーゼ阻害物質としての置換ピラゾロ［１，５−ａ］ピリジン化合物 |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| ES2948194T3 (es) | 2017-01-18 | 2023-09-01 | Array Biopharma Inc | Compuestos de pirazolo[1,5-a]pirazina sustituida como inhibidores de la cinasa RET |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| JP6997876B2 (ja) | 2018-01-18 | 2022-02-04 | アレイ バイオファーマ インコーポレイテッド | Ｒｅｔキナーゼ阻害剤としての置換ピラゾリル［４，３－ｃ］ピリジン化合物 |
| US11603374B2 (en) | 2018-01-18 | 2023-03-14 | Array Biopharma Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| TW201938169A (zh) | 2018-01-18 | 2019-10-01 | 美商亞雷生物製藥股份有限公司 | 作為RET激酶抑制劑之經取代吡唑并[3,4-d]嘧啶化合物 |
| JP7301958B2 (ja) | 2018-05-25 | 2023-07-03 | オンコキューブ セラピューティクス エルエルシー | 新規な抗がん薬候補としての非常に強力なｔａｃｃ３阻害剤 |
| CA3111984A1 (en) | 2018-09-10 | 2020-03-19 | Array Biopharma Inc. | Fused heterocyclic compounds as ret kinase inhibitors |
| EP4323351A4 (en) * | 2021-04-12 | 2025-07-30 | A2A Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER |
| WO2023183520A1 (en) | 2022-03-24 | 2023-09-28 | A2A Pharmaceuticals, Inc. | Compositions and methods for treating cancer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2308833A3 (en) * | 1999-04-15 | 2011-09-28 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| ES2257461T3 (es) * | 2000-12-21 | 2006-08-01 | Bristol-Myers Squibb Company | Inhibidores de tiazolilo de tirosina quinasas de la familia tec. |
| JP2006507302A (ja) * | 2002-10-30 | 2006-03-02 | メルク エンド カムパニー インコーポレーテッド | キナーゼ阻害剤 |
| CA2593803A1 (en) * | 2005-01-26 | 2006-08-03 | Irm Llc | Thiazole-amide compounds and compsitions as protein kinase inhibitors |
| PT2268635E (pt) | 2008-04-21 | 2015-10-06 | Taigen Biotechnology Co Ltd | Compostos heterocíclicos |
| WO2010046780A2 (en) | 2008-10-22 | 2010-04-29 | Institut Pasteur Korea | Anti viral compounds |
| EP2604601B1 (en) | 2010-08-10 | 2016-02-24 | Astellas Pharma Inc. | Hetero ring compound |
| US9255072B2 (en) * | 2011-03-04 | 2016-02-09 | National Health Rsearch Institutes | Pyrazole compounds and thiazole compounds as protein kinases inhibitors |
| JP6026544B2 (ja) | 2011-09-27 | 2016-11-16 | ノバルティス アーゲー | 変異体ｉｄｈの阻害剤としての３−ピリミジン−４−イル−オキサゾリジン−２−オン類 |
| CN104024246B (zh) * | 2012-03-27 | 2016-03-02 | 广东东阳光药业有限公司 | 作为欧若拉激酶抑制剂的取代嘧啶衍生物 |
-
2017
- 2017-01-26 TW TW106103165A patent/TWI620748B/zh active
- 2017-01-30 US US15/419,183 patent/US10047078B2/en active Active
- 2017-01-31 JP JP2018560435A patent/JP6883049B2/ja active Active
- 2017-01-31 CN CN201780010118.4A patent/CN109069504B/zh active Active
- 2017-01-31 EP EP17747997.9A patent/EP3411035B1/en active Active
- 2017-01-31 KR KR1020187024997A patent/KR102449712B1/ko active Active
- 2017-01-31 ES ES17747997T patent/ES2909612T3/es active Active
- 2017-01-31 WO PCT/US2017/015765 patent/WO2017136315A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019511564A5 (enExample) | ||
| JP2020007311A5 (enExample) | ||
| JP2020523348A5 (enExample) | ||
| JP5323289B1 (ja) | 新規ピペリジン化合物又はその塩 | |
| JP2015518899A5 (enExample) | ||
| JP2009536620A5 (enExample) | ||
| JP2017186337A5 (enExample) | ||
| JP2008528468A5 (enExample) | ||
| JP2009513703A5 (enExample) | ||
| EP2678336A1 (en) | Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors | |
| JP2018536705A5 (enExample) | ||
| JP2019511564A (ja) | アミノチアゾール化合物及びその使用 | |
| JP2016533379A5 (enExample) | ||
| JP2018516994A5 (enExample) | ||
| JP2014518544A5 (enExample) | ||
| RU2018102963A (ru) | Производные анилинпиримидина и их применения | |
| JP2017526662A5 (enExample) | ||
| CN118369119A (zh) | KRAS G12D抑制剂与泛ErbB家族抑制剂的组合疗法 | |
| CN116407639A (zh) | 具有失调的成纤维细胞生长因子受体信号转导的癌症的靶向治疗 | |
| JP2017501983A5 (enExample) | ||
| JP2016539153A5 (enExample) | ||
| JP2020534300A5 (enExample) | ||
| RU2015105786A (ru) | Комбинированная терапия ингибиторами igf1r и pi3k | |
| JPWO2020032105A5 (enExample) | ||
| JP2014532751A5 (enExample) |